Datasets:
hackint0sh
/
Text-Clinical-Records

Dataset card Data Studio Files Community
text
stringlengths
0
197k
Method: This study is a randomized controlled experimental study. It will be conducted with third-year students studying at Kastamonu University Midwifery Department in the 2023-2024 period. In the research, all third-year students in the midwifery department (n=60) will be divided into 30 students into the online education group and 30 students into the face-to-face education group using a random sampling model. "Student Information Form", "Episiotomy Skill Evaluation Form" and "Student Satisfaction and Self-Confidence in Learning Scale" will be used to collect data. conditions: Training Group, Sensitivity studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A comparative randomized controlled trial primaryPurpose: OTHER masking: SINGLE maskingDescription: After all students in the face-to-face education and online education groups complete their applications, the students will practice on the material one by one in the school environment and will be evaluated through the Episiotomy Skill Evaluation Form. In the evaluation, a blinding technique will be used to prevent the person conducting the study interventions from making an evaluation in favor of the intervention group. For this purpose, the faculty member conducting the research initiatives will not take part in the evaluation, instead the evaluation will be made by two different field experts. The experts to be consulted for the evaluation will consist of people working as academicians in the field of obstetrics, nursing and midwifery. After the evaluation, students will have to fill out the survey (Student Information Form) and scale (Student Satisfaction and Self-Confidence in Learning Scale). whoMasked: OUTCOMES_ASSESSOR count: 30 type: ESTIMATED name: Effect of training method measure: episiotomy skill performances measure: Satisfaction with education measure: Self-confidence in learning sex: FEMALE stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06283524 id: ETNA-TrainMS briefTitle: Eye-tracking Investigation of Clinical Measures in Multiple Sclerosis overallStatus: NOT_YET_RECRUITING date: 2024-03-18 date: 2025-10-18 date: 2026-03-18 date: 2024-02-28 date: 2024-02-28 name: Innodem Neurosciences class: INDUSTRY briefSummary: The overarching goal of this research protocol is to acquire eye-tracking, cognitive, and disease-severity metrics in MS patients to train machine learning algorithms that will support the development and performance assessment of a sensitive and non-invasive eye-tracking software application. The training of our machine learning classifying algorithms to identify which eye-tracking metrics-or combination thereof-can serve as reliable markers of MS disease severity and cognitive status. conditions: Multiple Sclerosis studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED name: Eye-Tracking measure: Predictive power of eye-movement biomarkers (EMBs) for MS severity in relationship to Expanded Disability Status Scale (EDSS) measure: Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Symbol Digit Modalities Test (SDMT) as part of the Brief International Cognitive Assessment for MS (BICAMS). measure: Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Rey Auditory Verbal Learning Test (RAVLT) as part of the Brief International Cognitive Assessment for MS (BICAMS). measure: Predictive power of eye-movement biomarkers (EMBs) for cognitive status in relationship to the Brief Visuospatial Memory Test-Revised (BVMT-R) as part of the Brief International Cognitive Assessment for MS (BICAMS). measure: Predictive power of eye-movement biomarkers (EMBs) for physical disability in relationship to the Timed 25-foot walk as part of the Multiple sclerosis functional composite (MSFC). measure: Predictive power of eye-movement biomarkers (EMBs) for physical disability in relationship to the 9-Hole Peg Test (9-HPT) as part of the Multiple sclerosis functional composite (MSFC). sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Genge Partners, Inc. city: Montréal state: Quebec zip: H4A 3T4 country: Canada name: Yousri Benchaar role: CONTACT phone: 514-906-3876 phoneExt: 6026 email: YBenchaar@gengepartners.com name: Alexander Saveriano, MD role: PRINCIPAL_INVESTIGATOR lat: 45.50884 lon: -73.58781 hasResults: False
<|newrecord|> nctId: NCT06283511 id: IJB-RESTART briefTitle: Evaluation of the RESTART Survival Programme overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2025-08 date: 2026-12 date: 2024-02-28 date: 2024-02-28 name: Jules Bordet Institute class: OTHER briefSummary: The RESTART survivorship programme has been implemented in the care pathway for patients with localised breast cancer since 2022. In this project, investigators are going to evaluate the satisfaction of patients taking part in the RESTART programme, as well as measuring changes in quality of life and health literacy after participation in the RESTART programme. conditions: Invasive Breast Cancer studyType: OBSERVATIONAL observationalModel: CASE_ONLY timePerspective: PROSPECTIVE count: 200 type: ESTIMATED name: educational workshops measure: Assessment of satisfaction with participation in the Restart programme and its various components via Likert scale and open questions. measure: assessment of quality of life measure: assessemnt of health literacy via HLQ questionnaire measure: assessment of professional status measure: assessment of level of physical activity measure: assessment of emotionnal distress measure: assessment of the intensity of residual fatigue measure: assessment of sleep quality measure: Measuring the rate of participation in the programme measure: assessment of quality of life measure: assessment of emotionnal distress sex: ALL minimumAge: 18 Years maximumAge: 99 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06283498 id: DO612574A briefTitle: Transvaginal Detrusor Nerve Radiofrequency Ablation for Treatment of Overactive Bladder overallStatus: ENROLLING_BY_INVITATION date: 2023-11-10 date: 2025-11 date: 2026-07 date: 2024-02-28 date: 2024-03-01 name: InMode MD Ltd. class: INDUSTRY briefSummary: The goal of this Safety and efficacy of transvaginal Detrusor Nerve Ablation for treatment of overactive bladder symptoms, including refractory overactive bladder
The main questions it aims to answer are:
•Change from baseline to the end of treatment in a 3-day diary analysis to assess the reduction of urgency incontinence episodes. \[Time Frame: 3 months\]
Subjects will undergo one treatment session and be reassessed at 4 weeks post-treatment. If less than a 50% improvement is noted, a second and third treatment session will be performed at 4-week intervals. If more than a 50% improvement is noted, patients will be followed longitudinally to assess the durability of the treatment. Investigators will have the ability to initiate a second and or third treatment on an individual basis.
Follow-up will occur at 3- months, 6-months and 12 months after the subject's last treatment. conditions: Overactive Bladder Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 20 type: ESTIMATED name: Device Morpheus8V measure: Change in urgency incontinence episodes after 3 month measure: Change in urgency incontinence episodes after 1 month measure: Change in urgency incontinence episodes measure: Change in urgency incontinence episodes measure: Analysis to assess the urinary frequency measure: Analysis to assess urinary frequency measure: Analysis to assess the urinary frequency. measure: Analysis to assess the urinary frequency. measure: Assessment of the impact of the treatment on Overactive Bladder symptoms measure: Assessment of the impact of the treatment on Overactive Bladder symptoms measure: Assessment of the impact of the treatment on Overactive Bladder symptoms measure: Assessment of the impact of the treatment on Overactive Bladder symptoms measure: Patient-reported Pain assessment measure: Patient-reported outcome measure measure: Patient-reported outcome measure measure: Patient-reported outcome measure measure: Patient-reported outcome measure sex: FEMALE minimumAge: 21 Years maximumAge: 80 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Mickey Karram MD city: Corona Del Mar state: California zip: 92625 country: United States lat: 33.59808 lon: -117.87311 facility: Institute for Female Pelvic Medicine city: Knoxville state: Tennessee zip: 37932 country: United States lat: 35.96064 lon: -83.92074 hasResults: False
<|newrecord|> nctId: NCT06283485 id: Study Artificial intelligence briefTitle: Real-time Anatomy Recognition Tool Accuracy Research for Ultrasound-guided PENG and Suprainguinal Fascia Iliaca Blocks overallStatus: RECRUITING date: 2023-12-15 date: 2024-04-01 date: 2024-05-25 date: 2024-02-28 date: 2024-02-28 name: Konya City Hospital class: OTHER name: Betül Afşar briefSummary: Background and rationale: Ultrasound-guided regional anesthesia is a widely used pain control method today. A critical aspect of the procedure is accurate visualization of anatomical structures on ultrasound to precisely define target areas. Distinguishing surrounding tissues with an imaging model that automatically recognizes sonoanatomy in ultrasound images will reduce unintended intraneural injections or injury to other anatomical structures in close proximity and increase patient safety.
Research question; How can we improve the ultrasound images we frequently use in regional blocks by integrating them with artificial intelligence to reduce complications and improve applications? And what is the accuracy of the developed artificial intelligence support during imaging?
Research purpose; This work; We aim to further increase the safety of different regional block positions, minimize the risk of complications, and improve ultrasound visualization by developing an artificial intelligence model (AI Model-Artificial Intelligence) that automatically identifies and segments anatomical landmarks, provides visual guidance for inexperienced colleagues, and improves the performance of the developed model during application. aims to demonstrate its accuracy.
Hypothesis; Numerous studies have shown that the use of ultrasound and neurostimulators in practice increases the success, onset and quality of nerve blocks, but due to the low incidence of major complications and the absence of comparable randomized studies, no definitive statement can be made as to whether ultrasound reduces the overall rate of nerve damage. An imaging model that automatically marks sonoanatomy with artificial intelligence in ultrasound images can reduce unintended intraneural injections or injury to other anatomical structures in close proximity and improve patient safety. conditions: Artificial Intelligent conditions: Ultrasound Therapy; Complications conditions: Nerve Block studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: CROSS_SECTIONAL count: 150 type: ESTIMATED name: ultrasound examination measure: Artificial intelligence Program size measure: Score of assessment the pictures sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Yasin Tire status: RECRUITING city: Konya state: Meram zip: 42140 country: Turkey name: Yasin Tire role: CONTACT phone: +905055367970 email: dryasintire@hotmail.com name: Betül Afşar role: CONTACT lat: 37.87135 lon: 32.48464 hasResults: False
<|newrecord|> nctId: NCT06283472 id: 1805574553; Aims 14-16 id: 2P60AA007611-403343 type: OTHER_GRANT domain: National Institute on Alcohol Abuse and Alcoholism id: 2P60AA007611 type: NIH link: https://reporter.nih.gov/quickSearch/2P60AA007611 briefTitle: Enhancing Prospective Thinking in Early Recovery (BEAM) acronym: BEAM overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2026-12-01 date: 2027-02-01 date: 2024-02-28 date: 2024-03-01 name: Indiana University class: OTHER briefSummary: The goal of this clinical trial is to test the prosocial effects of personally-relevant, high-intensity episodic future-thinking (EFT) cues in alcohol use disorder persons and related brain mechanisms. The main question\[s\] this trial aims to answer are:
* Will high-intensity EFT cues will produce greater delayed reward preference than low-intensity cues?
* Will high-intensity EFT cues effect greater treatment-seeking interest?
* Will high-intensity EFT cues elicit greater response in regions for prospective thinking during delay discounting (vs. low-intensity)
* Will nucleus accumbens-precuneus resting connectivity correlate with behavioral SS?
* Will the novel behavioral SS decision-making task activate the nucleus accumbens?
Researchers will compare the experimental (high-intensity group) and control (low-intensity) groups to see if there are differences in the results for the questions outlined above. conditions: Alcohol Use Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: Eligible participants will be randomly assigned to either the high-intensity (experimental) or low-intensity (control) groups. whoMasked: PARTICIPANT count: 150 type: ESTIMATED name: High-Intensity Cue name: Low-Intensity Cue measure: Increase Prospective Thinking measure: Delayed Rewards sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT hasResults: False
<|newrecord|> nctId: NCT06283459 id: 301-23-101 briefTitle: Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2 overallStatus: NOT_YET_RECRUITING date: 2024-04-01 date: 2025-09-30 date: 2025-09-30 date: 2024-02-28 date: 2024-04-05 name: Imunon class: INDUSTRY briefSummary: This is an open-label phase 1/2, dose-escalation study. Participants will receive a single intramuscular (IM) dose of IMNN-101 on Day 0 in the deltoid muscle and will be followed through 12 months post-vaccination (through Study Day 365). conditions: SARS CoV 2 Infection studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: PREVENTION masking: NONE count: 74 type: ESTIMATED name: IMNN-101 measure: Number of participants with local and systemic reactogenicity adverse events and all adverse events measure: Number of participants with geometric mean titer (GMT) of the serum neutralizing antibody (Nab) against the Omicron XBB.1.5 strain. measure: Number of participants with GMT of serum spike binding IgG antibodies measure: Number of participants with a magnitude and phenotype of cytokine producing S protein-specific T cells, as measured by flow cytometry and/or ELISpot. measure: Number of participants with seroresponse rate (SRR). sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Beth Israel Deaconess Medical Center city: Boston state: Massachusetts zip: 02215 country: United States name: Elizabeth Oginni role: CONTACT email: ooginni@bidmc.harvard.edu name: Ai-Ris Y Collier, MD role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: DM Clinical Research city: Philadelphia state: Pennsylvania zip: 19107 country: United States name: Kyle Bramble role: CONTACT email: kyle.bramble@dmclinical.com name: Kem Yenal, MD role: PRINCIPAL_INVESTIGATOR lat: 39.95233 lon: -75.16379 hasResults: False
<|newrecord|> nctId: NCT06283446 id: 1805574553; Aims 11-13 id: 1R21AA029760-01 type: NIH link: https://reporter.nih.gov/quickSearch/1R21AA029760-01 briefTitle: Enhancing Prospective Thinking in Early Recovery acronym: NERF overallStatus: RECRUITING date: 2023-12-20 date: 2024-07-31 date: 2024-07-31 date: 2024-02-28 date: 2024-02-28 name: Indiana University class: OTHER name: National Institute on Alcohol Abuse and Alcoholism (NIAAA) briefSummary: The goal of this clinical trial is to test the prosocial effects of personally-relevant, high-intensity episodic future-thinking (EFT) cues in alcohol use disorder persons and related brain mechanisms. The main question\[s\] this trial aims to answer are:
Will high-intensity EFT cues will produce greater delayed reward preference than low-intensity cues? Will high-intensity EFT cues effect greater treatment-seeking interest? Will high-intensity EFT cues elicit greater response in regions for prospective thinking during delay discounting (vs. low-intensity) Will nucleus accumbens-precuneus resting connectivity correlate with behavioral SS? Will the novel behavioral SS decision-making task activate the nucleus accumbens? Researchers will compare the experimental (high-intensity group) and control (low-intensity) groups to see if there are differences in the results for the questions outlined above. conditions: Alcohol Use Disorder studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: BASIC_SCIENCE masking: SINGLE maskingDescription: Eligible participants will be randomly assigned to either the high-intensity (experimental) or low-intensity (control) groups. whoMasked: PARTICIPANT count: 98 type: ESTIMATED name: High-Intensity Cue name: Low-Intensity Cue measure: Increase Prospective Thinking measure: Delayed Rewards sex: ALL minimumAge: 18 Years maximumAge: 60 Years stdAges: ADULT facility: Indiana University School of Medicine - Goodman Hall status: RECRUITING city: Indianapolis state: Indiana zip: 46202 country: United States name: Sarah Turo, BA role: CONTACT phone: 317-963-7220 email: sturo@iu.edu name: Colton Lind, BS role: CONTACT phone: 317-963-2554 email: cmlind@iu.edu name: Brandon G Oberlin, PhD role: PRINCIPAL_INVESTIGATOR lat: 39.76838 lon: -86.15804 hasResults: False
<|newrecord|> nctId: NCT06283433 id: NL83813.078.23 briefTitle: A Dried Blood Spot Sampling Method for Vancomycin and Creatinine Monitoring for OPAT acronym: ADVANCEDOPAT overallStatus: RECRUITING date: 2023-10-25 date: 2024-11 date: 2024-11 date: 2024-02-28 date: 2024-02-28 name: Erasmus Medical Center class: OTHER briefSummary: The Outpatient Parenteral Antibiotic Therapy (OPAT) service consists of providing antimicrobial therapy through parenteral infusion without hospitalization. This service is provided to stable patients otherwise ready for hospital discharge. Generally, the clinical monitoring for this patient population is minimal. However, clinical monitoring of vancomycin, an antibiotic widely used during OPAT, can be intensive primarily due to therapeutic drug monitoring. To ensure optimal treatment and minimize nephrotoxicity and microbial resistance, TDM and monitoring of serum creatinine levels are crucial during vancomycin therapy. TDM of vancomycin with OPAT presents a challenge for patients who must frequently travel to blood sampling facilities or the hospital for measurements. An alternative sampling method for TDM is the dried blood spot (DBS) method, which involves collecting a small drop of capillary blood from a finger prick onto filter paper. By implementing the DBS sampling method, the amount of outpatient visits regarding vancomycin treatment in OPAT can be reduced. Furthermore, the addition of measuring a biochemical parameter, such as renal function with serum creatinine, could lead to even less outpatient visits during OPAT. To date, studies investigating the effectiveness of DBS sampling of vancomycin and creatinine in terms of reducing outpatient visits have not yet been conducted in the OPAT population. conditions: Infection, Bacterial studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 84 type: ESTIMATED name: Finger Prick name: Venipuncture measure: To compare the number of outpatient visits in the control group versus the intervention group at day 28 measure: Outcomes regarding outpatient visit measure: Sampling outcomes measure: Satisfaction with blood sampling based on the theoretical framework of acceptability questionnaire (TFA) measure: Cost outcomes measure: Clinical outcomes measure: TDM outcomes measure: Logistical outcomes sex: ALL minimumAge: 18 Years maximumAge: 120 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus MC status: RECRUITING city: Rotterdam country: Netherlands name: Birgit Koch, PharmD role: CONTACT lat: 51.9225 lon: 4.47917 hasResults: False
<|newrecord|> nctId: NCT06283420 id: CarDia_WP5_P1_IRB:25059/23 briefTitle: Metabolic Response to Iniciation of Heart Failure Therapy acronym: GliF overallStatus: NOT_YET_RECRUITING date: 2024-02-21 date: 2025-12-20 date: 2026-12-20 date: 2024-02-28 date: 2024-02-28 name: Vojtech Melenovsky, MD, PhD class: OTHER_GOV briefSummary: This protocol is part of the CarDia project - National Institute for Metabolic and Cardiovascular Disease Research (EXCELES Program, ID: LX22NPO5104), funded by the European Union - Next Generation EU. The protocol is part of Work Package 5 (WP5): metabolic disorders in heart failure.
The goal of this observational protocol is to monitor the biochemical and metabolomic response to the initiation of therapy for heart failure with standard drugs (SGLT2i, sGC stimulators, ARNI) and whether this early response (within first 3 months) predicts the further course of the disease.
The protocol will examine how parameters reflecting neurohumoral activation, response to hypoxia, systemic metabolism of energy substrates, parameters of iron metabolism, HIF1A activation in peripheral blood behave over time after starting standard heart failure terapiy (baseline, 1 day, 1 week, 1 month, 3 month). This project can provide valuable information on how to identify people who respond more poorly to the treatment being introduced and are more at risk of an adverse course of the disease. Patients will be compared to patients who have no change of therapy over early observation period (3 mo), who will serve as controls. This is observational study, so decision to inicialize therapy will be based on medical indication.
Patients with heart failure treated at the IKEM Cardiocenter will have blood drawn at several defined intervals before and after the start of clinically indicated treatment. Some patients will also undergo genetic DNA testing to determine the variability of genes regulating the metabolic neurohumoral response to heart failure. Patients will be contacted at intervals of 1 and 2 years and the incidence of clinical events will be monitored. The study is observational in nature and inclusion in the study does not affect the course of care provided or the choice of pharmacotherapy. conditions: Heart Failure studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 120 type: ESTIMATED measure: hematocrit measure: HIF response measure: hepcidin sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Institute for Clinical end Experimental Medicine - IKEM city: Prague country: Czechia lat: 50.08804 lon: 14.42076 hasResults: False
<|newrecord|> nctId: NCT06283407 id: ICF briefTitle: ICF-based Comparison on Musculoskeletal Health in Poland and Spain overallStatus: NOT_YET_RECRUITING date: 2024-03-04 date: 2024-06-03 date: 2024-11-04 date: 2024-02-28 date: 2024-03-01 name: University of Rzeszow class: OTHER name: Sanidad de Castilla y León briefSummary: Musculoskeletal conditions are a major cause of disability worldwide. These conditions are often associated with chronicity, which is a challenge for healthcare systems to address. Health care must be person-centred and take into account the individual perspective from which the disease is experienced. The lived experience of health conditions depends to a large extent on contextual factors. Comparison between different contexts helps to identify which aspects are most relevant in the experience of the disease. The International Classification of Functioning, Disability and Health (ICF) provides a unified language that allows such comparisons to be made. The aim of this study is to identify differences in musculoskeletal health between the Polish and Spanish populations using the ICF as a frame of reference. conditions: Musculoskeletal Diseases or Conditions studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 800 type: ESTIMATED name: ICF-based cross-country comparative analysis measure: Brief International Classification of Functioning, Disability and Health (ICF) core set for post-acute musculoskeletal conditions measure: Sociodemographic data of the sample (nationality, age, sex, education level, work status, number of comorbidities) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Rzeszow city: Rzeszów zip: 35-959 country: Poland name: Agnieszka Wiśniowska-Szurlej role: CONTACT lat: 50.04132 lon: 21.99901 hasResults: False
<|newrecord|> nctId: NCT06283394 id: 854803 briefTitle: AHA (American Heart Association) Food is Medicine Test of Choice Architecture and Salience of Incentives overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-05-15 date: 2025-06-01 date: 2024-02-28 date: 2024-04-19 name: University of Pennsylvania class: OTHER briefSummary: The goal of this interventional study is to test ways to improve the effectiveness of a healthy foods prescription program in increasing the purchase of healthy foods for patients who have both obesity (BMI \> 30) and diabetes (last A1C\>8 in the last 90 days). The main questions it aims to answer are:
Aim 1: Examine feasibility and engagement among participants by assessing percent enrollment among those identified as eligible, rates of Instacart platform use, amount of the subsidy used each week, and amounts of healthy foods ordered.
Aim 2: Examine strategies to optimize the user experience of trial participation, including communication strategies and on-boarding, to increase uptake and engagement in this and subsequent studies.
Usual Care (Control): Participants in the usual care arm will not receive weekly subsidies on Instacart, and they will not receive any modifications to the virtual storefront on Instacart. They will have access to the standard Instacart platform and Instacart + memberships with $5 per week to cover service and delivery fees and delivery tips for 3 months.
Intervention Arms: The four treatment groups will also each receive a $160 subsidy per month for 3 months to be used on produce (fruits and vegetables). conditions: Obesity conditions: Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 180 type: ESTIMATED name: Storefront Choice Architecture name: Fresh Funds name: Loss Framing measure: The primary outcome will be the percentage of food purchasing expenditures spent on eligible healthy foods. measure: Percentage of the $160 subsidy used each month in the intervention arms. measure: Change in hemoglobin A1c measure: Qualitative results sex: ALL minimumAge: 30 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06283381 id: 4264 briefTitle: The ESG Integrity Study: Effect of Proton Pump Inhibitors on the Structural Integrity of Endoscopic Sleeve Gastroplasty acronym: ESGIS overallStatus: RECRUITING date: 2024-02-01 date: 2025-01-31 date: 2026-06-30 date: 2024-02-28 date: 2024-02-28 name: Fondazione Policlinico Universitario Agostino Gemelli IRCCS class: OTHER briefSummary: The study is a single center randomized, open-label, phase IV clinical trial. Obese patients who have indication to Endoscopic sleeve gastroplasty (ESG) for clinical reasons are included and ESG is performed as per clinical practice. After randomization, the patients are divided in two arms:
* Arm A: patients will stop proton pump inhibitors (PPI) 24h after the procedure.
* Arm B: patients will assume oral Esomeprazole 40 mg twice a day for 4 weeks and 40 mg once a day for 4 weeks (total 8 weeks of PPIs after ESG- standard current treatment).
The primary aim of the study is to evaluate the effect of PPI on the structural integrity of the ESG conditions: Obesity studyType: INTERVENTIONAL phases: PHASE4 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Esomeprazole measure: The structural integrity of the sutures after Endoscopic sleeve gastroplasty (ESG) sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Fondazione Policlinico Universitario A. Gemelli IRCCS status: RECRUITING city: Roma zip: 00168 country: Italy name: IVO BOSKOSKI role: CONTACT phone: +390630155701 email: ivo.boskoski@policlinicogemelli.it name: IVO BOSKOSKI role: PRINCIPAL_INVESTIGATOR lat: 41.89193 lon: 12.51133 hasResults: False
<|newrecord|> nctId: NCT06283368 id: 2021/11-06 briefTitle: Red Blood Cell Distributions (RDW, RDW-CW) and Lymphocyte Monocyte Ratios (LMR) for the Malignant Thyroid Nodules overallStatus: COMPLETED date: 2016-01 date: 2021-01 date: 2021-01 date: 2024-02-28 date: 2024-03-01 name: Kahramanmaras Sutcu Imam University class: OTHER briefSummary: Thyroid surgery is the most common type of surgery among endocrine surgeries. This surgery is performed for patients with suspected malignancy, patients diagnosed with malignancy, and toxic nodular goiter. In addition to vocal cord injury, which is the most important complication of thyroid surgery, hypocalcemia due to hypoparathyroidism and surgical wound complications (such as hematoma, and fistula) can also be observed, and malignancy surgery increases the risk of recurrent laryngeal nerve injury. Therefore, it is important to differentiate these groups using non-invasive methods before surgery.
Tumor-related inflammation is activated as a result of bone marrow and inflammation induced by malignancies. Insufficiently controlled or uncontrolled inflammatory activity may be responsible for malignant transformation. Lymphocyte monocyte ratio and red blood cell distribution are parameters (RDW, RDW-CW) previously studied in terms of cancers.
Our aim in this study is to reveal the RDW, RDW-CW, and LMR calculated from complete blood count parameters in the preoperative period, as an indicator of malignant inflammatory response, in a non-invasive and inexpensive way before surgery or biopsy is performed to distinguish nodular goiter and thyroid malignancy. conditions: Thyroid Neoplasms Benign conditions: Thyroid Nodule conditions: Thyroid Cancer conditions: Thyroid Diseases studyType: OBSERVATIONAL observationalModel: CASE_CONTROL timePerspective: RETROSPECTIVE count: 172 type: ACTUAL name: Thyroidectomy, Bilaterally Total name: Thyroidectomy, Unilaterally Total name: Thyroidectomy, Complementary name: Thyroidectomy, Near Total measure: Determining benign thyroid nodules measure: Determining malignant thyroid nodules sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06283355 id: IRB00433691 briefTitle: Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome overallStatus: NOT_YET_RECRUITING date: 2024-05-15 date: 2025-06-01 date: 2025-12-31 date: 2024-02-28 date: 2024-02-28 name: Johns Hopkins University class: OTHER briefSummary: This study aims to determine whether a parent-to-child nasal microbiota transplant (NMT) can seed and engraft parental organisms into the neonatal microbiome and increase the neonatal microbiome diversity. conditions: Staphylococcus Aureus conditions: Microbial Colonization conditions: Neonatal Infection studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: NONE count: 175 type: ESTIMATED name: Nasal Microbiota Transplant (NMT) name: Placebo measure: Neonatal nasal microbiome diversity after intervention sex: ALL minimumAge: 0 Years maximumAge: 60 Years stdAges: CHILD stdAges: ADULT facility: Johns Hopkins University city: Baltimore state: Maryland zip: 21287 country: United States name: Danielle Koontz role: CONTACT phone: 443-287-9040 email: dkoontz1@jhmi.edu name: Aaron Milstone role: PRINCIPAL_INVESTIGATOR lat: 39.29038 lon: -76.61219 hasResults: False
<|newrecord|> nctId: NCT06283342 id: Konya Pediatric Hematology briefTitle: Prophylactic Iron and Nutrition in Preventing Infant Iron Deficiency overallStatus: COMPLETED date: 2018-01-01 date: 2019-01-01 date: 2019-02-01 date: 2024-02-28 date: 2024-02-28 name: Konya Meram State Hospital class: OTHER briefSummary: This study aimed to reveal the effects of prophylactic iron preparations, adequate breast milk intake, and iron-rich supplementary food intake in the prevention of IDA (iron deficiency anemia) and ID (iron deficiency) in infancy. conditions: Iron Deficiency Anemia in Childbirth conditions: Infant Nutrition Disorders conditions: Iron Deficiencies studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 2 type: ACTUAL measure: Ferritine level measure: Hemoglobin level measure: Prophylactic iron use rate measure: Iron-sufficient supplementary food intake rate of babies measure: Breast milk usage rate sex: ALL minimumAge: 6 Months maximumAge: 24 Months stdAges: CHILD facility: Konya Training and Research Hospital city: Konya zip: 42090 country: Turkey lat: 37.87135 lon: 32.48464 hasResults: False
<|newrecord|> nctId: NCT06283329 id: echographic VC curarization briefTitle: Residual Vocal Cords Curarization Correlation Between Clinical and Ultrasound Endpoints overallStatus: COMPLETED date: 2023-12-01 date: 2023-12-31 date: 2023-12-31 date: 2024-02-28 date: 2024-02-28 name: General Administration of Military Health, Tunisia class: NETWORK briefSummary: Through recent studies residual curarization (RC) remains frequent but serious event, that could be easily avoided in the presence of a paraclinical monitoring and by antagonization of curares. However, conventional monitors focus only on peripheral muscles, whereas ultrasonography allows direct visualization of laryngeal muscles, particularly the vocal cords, which are directly influenced by neuromuscular blocking agents. The aim of the study was to evaluate the ultrasound mobility of the vocal cords after awakening and extubation of general anesthesia compared to their preoperative mobility and its correlation with clinical and paraclinical diagnostic criteria (DG) for RC. conditions: Residual Curarization studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 70 type: ACTUAL name: vocal cords echography measure: Echographic mobility of vocal cords at different times in post extubation sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Elaskri Haythem city: Tunis zip: 1008 country: Tunisia lat: 36.81897 lon: 10.16579 hasResults: False
<|newrecord|> nctId: NCT06283316 id: 11347 briefTitle: Systemic Treatments for Alopecia Areata Registry acronym: STA2R overallStatus: RECRUITING date: 2024-01-17 date: 2099-12-31 date: 2099-12-31 date: 2024-02-28 date: 2024-02-28 name: Erasmus Medical Center class: OTHER briefSummary: A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes. conditions: Alopecia Areata conditions: Alopecia Totalis conditions: Alopecia Universalis conditions: Hair Loss conditions: Hair Diseases conditions: Alopecia conditions: Alopecia Drugs conditions: Autoimmune Diseases studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 10000 type: ESTIMATED measure: Effectiveness of systemic treatments measure: Safety of systemic treatments measure: Epidemiological data measure: Physician Reported - Severity of Alopecia Tool (SALT Score) measure: Dermatology Life Quality Index (DLQI, 10 items) measure: Alopecia Areata Symptom Impact Scale (AASIS, 13 items) sex: ALL minimumAge: 16 Years stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: Erasmus University Medical Center status: RECRUITING city: Rotterdam country: Netherlands name: DirkJan Hijnen, MD, PhD role: CONTACT phone: 0031 10 704 01 10 email: d.hijnen@erasmusmc.nl lat: 51.9225 lon: 4.47917 hasResults: False
<|newrecord|> nctId: NCT06283303 id: MVR-T3011-HAI-01 briefTitle: A Clinical Study of T3011 in Combination With Toripalimab and Regorafenib in Patients With Colorectal Cancer overallStatus: NOT_YET_RECRUITING date: 2024-04-02 date: 2025-11-30 date: 2025-11-30 date: 2024-02-28 date: 2024-02-29 name: China Medical University, China class: OTHER name: Immvira Co., Limited briefSummary: This is a phase I, open-label clinical study of T3011 in combination with Toraplizumab and Regorafenib in patients with liver metastases from colorectal cancer. conditions: Colorectal Cancer Metastatic studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 8 type: ESTIMATED name: T3011 hepatic artery infusion name: toripalimab name: regorafenib measure: Treatment Emergent Adverse Event（TEAE） measure: Objective response rate (ORR) measure: Overall survival (OS) measure: Progression-free survival (PFS) sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06283290 id: D3250R00122 briefTitle: PROPE Severe Asthma Study in Egypt overallStatus: RECRUITING date: 2024-03-12 date: 2024-07-31 date: 2024-07-31 date: 2024-02-28 date: 2024-04-19 name: AstraZeneca class: INDUSTRY briefSummary: Asthma is a syndrome characterized by airway inflammation, reversible airway obstruction, and airway hyper-responsiveness. Patients present clinically with recurrent wheezing, shortness of breath, cough, and chest tightness. Asthma is a leading cause of morbidity with a global prevalence of approximately 300 million; it is estimated that the number of people with asthma may increase to 400 to 450 million people worldwide by 2025.
Severe asthma is not considered a single disease; instead, it is divided into several phenotypes, owing to the variety of inflammatory, clinical, and functional characteristics that it can present with. One of the proposed and most studied phenotypes is severe eosinophilic asthma. Patients with severe asthma that is accompanied by a high concentration of eosinophils require greater healthcare resource use, greater disease management costs, and a much more impaired QoL than those who do not present with raised eosinophilia.
While the number of targeted treatments for asthma management has been growing in recent years, the heterogeneity of clinical presentations, treatment responses, and inflammatory processes involved represent an added challenge for health care professionals. Thus, severe asthma management is a complex endeavor, and a thorough and up-to-date understanding of the pathophysiologic characteristics of the patient population promotes effective therapeutic decision-making.
This cross-sectional, multicenter study aims to determine the prevalence of oral corticosteroid (OCS) use among severe asthma patients who attend to different sites specialized in the management of severe asthma across Egypt. In addition, the prevalence of eosinophilic phenotype of blood eosinophil count ≥ 150 cells/mm3, prevalence of atopic phenotype, and asthma control will also be studied. conditions: Severe Asthma studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 150 type: ESTIMATED measure: To describe the prevalence (frequency) of OCS use among severe asthma patients as defined by chronic treatment and/or bursts of OCS use. measure: To describe the demographic characteristics of severe eosinophilic asthma patients. measure: To describe the clinical characteristics of severe eosinophilic asthma patients. measure: To discover the average OCS dose per year used among severe asthma patients. measure: To determine the prevalence of the eosinophilic phenotype measure: To determine the prevalence of the eosinophilic phenotype measure: To determine the prevalence of the total serum IgE measure: To determine the annual severe asthma exacerbation rate in the past twelve months among severe asthma patients in Egypt measure: To evaluate asthma control of severe asthma patients measure: To evaluate comorbidities related to OCS use sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Research Site status: NOT_YET_RECRUITING city: Mansoura state: Dakahlia country: Egypt lat: 31.03637 lon: 31.38069 facility: Research Site status: RECRUITING city: Zagazig state: Sharkia country: Egypt lat: 30.58768 lon: 31.502 facility: Research Site status: RECRUITING city: Alexandria country: Egypt lat: 31.21564 lon: 29.95527 facility: Research Site status: RECRUITING city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 facility: Research Site status: NOT_YET_RECRUITING city: Cairo country: Egypt lat: 30.06263 lon: 31.24967 hasResults: False
<|newrecord|> nctId: NCT06283277 id: fetal macrosomia briefTitle: Fetal Clavicular Measurement to Predict Fetal Macrosomia overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2027-04-30 date: 2027-10-30 date: 2024-02-28 date: 2024-02-28 name: Assiut University class: OTHER briefSummary: Macrosomia is associated with increased risks for both the mother and the baby, including complications during delivery, injuries, and even death. The accurate diagnosis of macrosomia is often difficult before birth. There are a number of factors that can increase the risk of macrosomia, such as maternal obesity, diabetes, and excessive weight gain during pregnancy. There are also a number of different techniques that can be used to try to predict macrosomia, but none of them are perfect.
The aim of this study is to evaluate sensitivity of measuring fetal clavicle length in third trimester compared with biacromial diameter and Hadlock formula IV for prediction of fetal macrosomia. conditions: Macrosomia, Fetal conditions: Large for Gestational Age conditions: Shoulder Dystocia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 240 type: ESTIMATED name: Obstetric Ultrasound measure: Third trimester clavicle length measurement measure: Establish the relationship between third-trimester clavicle length and shoulder dystocia measure: Mode of delivery measure: Gestational age at the time of delivery. measure: Neonatal Apgar score. measure: Neonatal bi-acromial diameter measure: Neonatal birth weight measure: Neonatal need for NICU measure: Neonatal actual clavicle length sex: FEMALE minimumAge: 18 Years maximumAge: 45 Years stdAges: ADULT hasResults: False
<|newrecord|> nctId: NCT06283264 id: Coeliac Disease in type2 DM briefTitle: Assessment of Coeliac Disease in Patients With Type 2 Diabetes overallStatus: NOT_YET_RECRUITING date: 2024-03-15 date: 2026-12-01 date: 2026-12-30 date: 2024-02-28 date: 2024-02-28 name: Assiut University class: OTHER briefSummary: This study aims to screen and diagnose coeliac disease in patients with type 2 diabetes and monitor the effect of gluten-free diet on the metabolic status conditions: Celiac Disease studyType: OBSERVATIONAL observationalModel: OTHER timePerspective: CROSS_SECTIONAL count: 100 type: ESTIMATED measure: 1-Prevalence of coeliac disease among diabetic type 2 patient 2-its effect on glycemic control sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06283251 id: 23-590 briefTitle: PediRISE Feasibility overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2024-12-31 date: 2024-12-31 date: 2024-02-28 date: 2024-02-28 name: Dana-Farber Cancer Institute class: OTHER name: American Cancer Society, Inc. name: Children's Cancer Research Fund briefSummary: The goal of this research study is to learn whether investigators can successfully give the PediRISE program to families-in other words, whether most families are interested in participating in a study about the PediRISE program, including a 50-50 chance of receiving standard usual care, and a 50-50 chance of receiving the PediRISE support program.
The names of the study groups in this research study are:
* PediRISE Program Group
* Usual Care Group conditions: Pediatric Cancer conditions: Financial Stress conditions: Financial Hardship conditions: Disparities studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: SUPPORTIVE_CARE masking: NONE count: 40 type: ESTIMATED name: PediRISE Resource Program measure: Rate of Participant Consent measure: 6-Month Follow Up Rate for PediRISE Program Group measure: 6-Month Follow Up Rate for Usual Care Group sex: ALL maximumAge: 17 Years stdAges: CHILD facility: Boston Children's Hospital city: Boston state: Massachusetts zip: 02215 country: United States name: Kira Bona, MD, MPH role: CONTACT phone: 617-632-4688 email: Kira_Bona@dfci.harvard.edu name: Kira Bona, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 facility: Dana Farber Cancer Institute city: Boston state: Massachusetts zip: 02215 country: United States name: Kira Bona, MD, MPH role: CONTACT phone: 617-632-4688 email: Kira_Bona@dfci.harvard.edu name: Kira Bona, MD, MPH role: PRINCIPAL_INVESTIGATOR lat: 42.35843 lon: -71.05977 hasResults: False
<|newrecord|> nctId: NCT06283238 id: Pro00115121 briefTitle: Biobanking Upper Gastrointestinal Tumors to Evaluate Response (BURGER With BACON) overallStatus: NOT_YET_RECRUITING date: 2024-04-25 date: 2026-03-25 date: 2027-03-25 date: 2024-02-28 date: 2024-02-28 name: Duke University class: OTHER briefSummary: The goal of this observational study is to examine genetic changes that may contribute to immunotherapy resistance in gastroesophageal cancer. This information can potentially lead to the identification of new immunotherapeutic targets as well as improve the ability to identify those patients more likely to respond to immunotherapy.
This study does not include any treatment or investigational drugs.
Participants will be asked:
* to enroll before beginning standard care of treatment for their cancer
* for blood, archived tumor tissue, and fresh tumor tissue Researchers will compare participants who are not getting immunotherapy to identify potential differences in expression levels of a gene. conditions: GastroEsophageal Cancer studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: OTHER count: 500 type: ESTIMATED name: Immune checkpoint inhibitor (ICI) or chemotherapy alone measure: Number of participants with Complete Response (CR) measure: Number of participants with Partial Response (PR) measure: Number of participants with Stable Disease measure: Number of participants with Progressive Disease sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Duke University city: Durham state: North Carolina zip: 27710 country: United States lat: 35.99403 lon: -78.89862 hasResults: False
<|newrecord|> nctId: NCT06283225 id: RCT004_PilotPia briefTitle: Pilot Study to Investigate the Effect of a Dysmenorrhoea App overallStatus: NOT_YET_RECRUITING date: 2024-02 date: 2024-07 date: 2024-07 date: 2024-02-28 date: 2024-03-01 name: Endo Health GmbH class: INDUSTRY briefSummary: The pilot study investigates the influence of a dysmenorrhoea app on the quality of life and symptoms of women with dysmenorrhoea. The intervention group can use the app over the study period of 12 weeks in addition to usual care, while the control group only receives the usual standard care. The aim is to evaluate the effectiveness of the app and to gain insights for the design of future studies. The study is expected to last seven months and include 100-200 participants. conditions: Dysmenorrhea studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: intervention group and control group primaryPurpose: SUPPORTIVE_CARE masking: DOUBLE whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 100 type: ESTIMATED name: Pia-App measure: Dysmenorrhea Symptom Interference Scale (DSI) measure: Moos Menstrual Distress Questionnaire, Form C (MDQ) measure: Visual analog scale (VAS) measure: Depression Anxiety Stress Scale mit 21 Items (DASS-21) measure: German Version of Pain Self-Efficacy Questionnaire (FESS) measure: Fatigue Severity Scale (FSS) measure: Pain Disability Index (PDI) sex: FEMALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
<|newrecord|> nctId: NCT06283212 id: ETX-DS-005 briefTitle: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Children With SCN1A-positive Dravet Syndrome acronym: UK Only overallStatus: RECRUITING date: 2024-04 date: 2029-12 date: 2029-12 date: 2024-02-28 date: 2024-04-17 name: Encoded Therapeutics class: INDUSTRY briefSummary: EXPEDITION is a Phase 1/2 study in the UK to evaluate the safety and efficacy of ETX101 in participants with SCN1A-positive Dravet Syndrome aged 6 to \< 48 months. The study follows and open-label, dose-escalation design. conditions: Dravet Syndrome studyType: INTERVENTIONAL phases: PHASE1 phases: PHASE2 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL primaryPurpose: TREATMENT masking: NONE count: 4 type: ESTIMATED name: ETX101 measure: Proportions of participants experiencing any treatment-emergent adverse events (AEs), serious adverse events (SAEs), related AEs, AEs with severity Grade ≥ 3, AEs resulting in study discontinuation, and AEs with fatal outcome. measure: Change from baseline in the standard score of the Vineland Adaptive Behavior Scales - Third Edition Adaptive Behavior Composite at Week 52. measure: Percent change in monthly countable seizure frequency (MCSF) to Week 52, with countable seizures defined as generalized tonic-clonic/clonic, focal motor with clearly observable clinical signs, tonic bilateral, and atonic seizures. measure: Change from baseline in the raw score of the Bayley Scales of Infant and Toddler Development® 4th Edition receptive language sub-domain at Week 52. sex: ALL minimumAge: 6 Months maximumAge: 47 Months stdAges: CHILD facility: Queen Elizabeth Hospital status: RECRUITING city: Glasgow zip: G51 4TF country: United Kingdom name: Patricia Clark role: CONTACT phone: 0141 232 7600 email: Patricia.Clark2@ggc.scot.nhs.uk lat: 55.86515 lon: -4.25763 facility: Great Ormond Street Hospital status: NOT_YET_RECRUITING city: London zip: WC1N3JH country: United Kingdom name: Helen Cross, MD role: CONTACT email: helen.cross10@nhs.net lat: 51.50853 lon: -0.12574 facility: Sheffield Children's Hospital status: NOT_YET_RECRUITING city: Sheffield zip: S10 2TH country: United Kingdom name: Research Team role: CONTACT email: research.sheffchild@nhs.net lat: 53.38297 lon: -1.4659 hasResults: False
<|newrecord|> nctId: NCT06283199 id: ORL-ORT-025 briefTitle: Comparing Reports Recorded by the Patients at the Time at Which They Feels Pain to What Patients Report at Monthly Visits to Assess Symptoms of Musculoskeletal Diseases. overallStatus: RECRUITING date: 2021-04-06 date: 2027-12-31 date: 2027-12-31 date: 2024-02-28 date: 2024-03-01 name: Ente Ospedaliero Cantonale, Bellinzona class: OTHER briefSummary: Patients will be introduced to the use of a mobile application for their smartphone to record the Ecological Momentary Assessment (EMA). This app will ask the patients to assess their pain and function two times daily for 2 months.
After 1 month and at the end of the 2 months, follow-up visits will be performed and patients will be asked to retrospectively evaluate the pain that they suffered and the level of function they had during the last month. conditions: Musculoskeletal Pain studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: PROSPECTIVE count: 1500 type: ESTIMATED measure: Difference in pain level sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: IRCCS Istituto Ortopedico Rizzoli status: RECRUITING city: Bologna country: Italy name: Alessandro Di Martino, MD role: CONTACT phone: 0039 051 6366567 email: alessandro.dimartino@ior.it lat: 44.49381 lon: 11.33875 facility: EOC - Orthopaedics and Traumatology Service status: RECRUITING city: Lugano zip: 6900 country: Switzerland name: Christian Candrian, Prof.Dr.med role: CONTACT phone: +41 (0) 91 811 61 23 email: christian.candrian@eoc.ch lat: 46.01008 lon: 8.96004 hasResults: False
<|newrecord|> nctId: NCT06283186 id: CSEULS-PI-004/2024 briefTitle: Comparative Exercise-Induced Hypoalgesia in Upper and Lower Limbs: A Randomized Controlled Trial in Healthy Individuals overallStatus: RECRUITING date: 2024-04-23 date: 2025-07-31 date: 2025-07-31 date: 2024-02-28 date: 2024-04-24 name: Centro Universitario La Salle class: OTHER briefSummary: This randomized controlled trial with healthy subjects aims to compare exercise-induced hypoalgesia among three groups: one utilizing a lower limb cycle ergometer, another using an upper limb cycle ergometer, and a control group. The exercise protocol involves 30 minutes of aerobic activity at 70-80% of the heart rate reserve. Exercise-induced hypoalgesia will be assessed by measuring pressure pain thresholds in the thigh and elbow. Additionally, a secondary objective is to compare the lower limb and upper limb cycle ergometer groups in terms of their effects on pressure pain thresholds in the thigh and elbow. Thus, the study anticipates observing differences in local and distal hypoalgesia based on the trained region. conditions: Healthy Subjects studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 90 type: ESTIMATED name: Aerobic exercise name: Aerobic exercise measure: Pressure pain threshold (PPT) on dominant quadriceps and dominant lateral epicondyle measure: International Physical Activity Questionnaire (IPAQ) measure: Fatigue Assessment Scale (FAS) measure: Heart rate measure: Rate of perceived exertion (RPE) measure: Physical Activity Readiness Questionnaire (PAR-Q) sex: ALL minimumAge: 18 Years maximumAge: 64 Years stdAges: ADULT facility: CSEU LaSalle status: RECRUITING city: Madrid zip: 28023 country: Spain name: Álvaro Reina-Varona, MSc role: CONTACT phone: 0034 + 649001863 email: alvaroreina93@gmail.com name: Álvaro Reina-Varona, MSc role: PRINCIPAL_INVESTIGATOR lat: 40.4165 lon: -3.70256 hasResults: False
<|newrecord|> nctId: NCT06283173 id: 23-401 briefTitle: HRIPT for Collagen Dressing overallStatus: COMPLETED date: 2024-01-31 date: 2024-03-22 date: 2024-03-22 date: 2024-02-28 date: 2024-04-16 name: Covalon Technologies Inc. class: INDUSTRY name: ALS Beauty and Personal Care briefSummary: The objectives of this study are to determine by repetitive epidermal contact, the primary or cumulative irritation and the allergic contact sensitization potential of the ColActive Plus Collagen Matrix Dressing, under maximized conditions, with controlled product quantity and application site. conditions: Skin Sensitisation studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This will be a single center, with no randomization or blinding, study design in 50 healthy adult subjects, age 18-70 years. Based on prior experience approximately 75 subjects will be enrolled to ensure 50 subjects complete the study. primaryPurpose: OTHER masking: NONE count: 57 type: ACTUAL name: ColActive Plus Collagen Matrix Dressing measure: Skin sensitization reaction using Berger and Bowman scale measure: Skin irritation reaction using Berger and Bowman scale measure: Skin sensitization reaction using Berger and Bowman scale measure: Skin sensitization reaction using Berger and Bowman scale sex: ALL minimumAge: 18 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: ALS Beauty and Personal Care city: Torrance state: California zip: 90501 country: United States lat: 33.83585 lon: -118.34063 hasResults: False
<|newrecord|> nctId: NCT06283160 id: 2023/834 briefTitle: Metabolomic and Immune Profiling in the Development of Pancreatic Fistulas After Cephalic Duodenopancreatectomy acronym: PROMETHEE overallStatus: RECRUITING date: 2024-03-01 date: 2026-05-30 date: 2026-05-30 date: 2024-02-28 date: 2024-04-12 name: Centre Hospitalier Universitaire de Besancon class: OTHER briefSummary: Pancreaticoduodenectomy is the standard surgical operation for benign or malign pancreatic lesions. Pancreatic Fistula (PF) or Postpancreatectomy Acute Pancreatitis (PPAP) are the major complications associated with that type of surgery. We need to develop preventive measures for these complications, which requires a better understanding of their physiopathology.